List view / Grid view
22 January 2016 | By Victoria White
The EC has approved the Type II variation for Adcetris to include data on the retreatment of adult patients with R/R Hodgkin lymphoma or R/R sALCL who previously responded to Adcetris and who later relapse....
17 December 2015 | By Victoria White
AstraZeneca is to acquire the core respiratory business of Takeda for $575 million, adding Daxas to its portfolio...
14 December 2015 | By Victoria White
Takeda’s Ninlaro (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the US for patients with multiple myeloma...
7 December 2015 | By Victoria White
Takeda presented long-term data from a Phase II and Phase III trial of Adcetris (brentuximab vedotin) at the 57th American Society of Hematology (ASH) annual meeting...
23 November 2015 | By Victoria White
Ninlaro (ixazomib) is the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma...
27 October 2015 | By Victoria White
Data from a Phase 1 trial evaluating Adcetris plus AVD demonstrated that 24 of 25 patients (96 percent) achieved a complete remission...
10 September 2015 | By Victoria White
Ixazomib is the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma...
26 August 2015 | By Victoria White
NICE has recommended Vedolizumab, the first gut-selective treatment for Crohn's Disease, for use on the NHS, recognising the innovation of the treatment...
21 August 2015 | By Victoria White
Takeda has announced that the EMA has accepted is Marketing Authorisation Application for ixazomib for the treatment of patients with multiple myeloma...
27 July 2015 | By Victoria White
The CHMP of the EMA has granted an accelerated assessment to ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma...
15 July 2015 | By Victoria White
Takeda has submitted an NDA to the US FDA for ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma...
22 June 2015 | By Victoria White
Results from a new sub-analysis of the Phase 3 Aethera clinical trial of Adcetris were presented at the 13th International Conference on Malignant Lymphoma...
15 May 2015 | By Victoria White
Takeda has decided to discontinue the Phase 3 trial of alisertib (MLN8237) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)...
12 May 2015 | By Victoria White
Takeda has announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib...
31 March 2015 | By Victoria White
Takeda and Sunovion today announced the results from 3 post-hoc analyses evaluating the efficacy and safety of lurasidone in patients with schizophrenia...
